923591-35-9Relevant academic research and scientific papers
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor
McCauley, John A.,McIntyre, Charles J.,Rudd, Michael T.,Nguyen, Kevin T.,Romano, Joseph J.,Butcher, John W.,Gilbert, Kevin F.,Bush, Kimberly J.,Holloway, M. Katharine,Swestock, John,Wan, Bang-Lin,Carroll, Steven S.,Dimuzio, Julian M.,Graham, Donald J.,Ludmerer, Steven W.,Mao, Shi-Shan,Stahlhut, Mark W.,Fandozzi, Christine M.,Trainor, Nicole,Olsen, David B.,Vacca, Joseph P.,Liverton, Nigel J.
experimental part, p. 2443 - 2463 (2010/09/03)
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular-modeling derived strategy. Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of
HCV NS3 protease inhibitors
-
Page/Page column 96, (2008/06/13)
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
